Aaron Trachtenberg

Aaron Trachtenberg

Auto-generated profile, based on publicly available information

Aaron Trachtenberg

Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JHJulie Ho
Julie Ho
GOGeorge N. Okoli
George N. Okoli
RRRasheda Rabbani
Rasheda Rabbani
OLOtto Lam
Otto Lam
VRViraj K. Reddy
Viraj K. Reddy
AAAhmed M. Abou-Setta
Ahmed M. Abou-Setta
The effectiveness of T cell-mediated rejection (TCMR) therapy for achieving histological remission remains undefined in patients on modern immunosuppression. We systematically identified, critically appraised and summarized the incidence and histological outcomes after TCMR treatment in patients on tacrolimus (Tac) and mycophenolic acid (MPA). English-language publications were searched in MEDLINE (Ovid), Embase (Ovid), Cochrane Central (Ovid), CINAHL (EBSCO), Clinicaltrials.gov (NLM) up to January 2021. Study quality was assessed with National Institutes of Health Study Quality Tool. We pooled results using an inverse variance, random-effects model and report the binomial proportions with associated 95% confidence intervals (95% CI). Statistical heterogeneity was explored using the I2 statistic. From 2,875 screened citations, we included 12 studies (1,255 participants). Fifty-eight percent were good/high quality while the rest were moderate quality. Thirty-nine percent of patients (95%CI 0.26-0.53, I2 77%) had persistent ≥Banff Borderline TCMR 2-9 months after anti-rejection therapy. Pulse steroids and augmented maintenance immunosuppression were mainstays of therapy, but considerable practice heterogeneity was present. A high proportion of biopsy-proven rejection exists after treatment emphasizing the importance of histology to characterize remission. Anti-rejection therapy is foundational to transplant management but well-designed clinical trials in patients on Tac/MPA immunosuppression are lacking to define the optimal therapeutic approach.

4 August 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
CWChris Wiebe
Chris Wiebe
RBRobert Balshaw
Robert Balshaw
IGIan W. Gibson
Ian W. Gibson
JHJulie Ho
Julie Ho
JSJamie Shaw
Jamie Shaw
PNPeter W. Nickerson
Peter W. Nickerson
De novo DSA (dnDSA) after renal transplantation has been shown to correlate with antibody-mediated rejection and allograft loss. However, the lack of proven interventions and the time and cost associated with annual screening for dnDSA are difficult to justify for all recipients. We studied a well-characterized consecutive cohort (n=949) with over fifteen years of prospective dnDSA surveillance to identify risk factors that would help institute a resource-responsible surveillance strategy. Younger recipient age and HLA-DR/DQ molecular mismatch were independent predictors of dnDSA development. Combining both risk factors into Recipient Age Molecular Mismatch (RAMM) categories we found that 52% of recipients could be categorized as low-risk for dnDSA development (median subclinical dnDSA-free survival at 5 and 10 years 98% and 97%). After adjustment, multivariate correlates of dnDSA development included tacrolimus versus cyclosporin maintenance immunosuppression (HR 0.37, 95%CI 0.2-0.6, p<0.0001), and RAMM category intermediate versus low (HR 2.48, 95%CI 1.5-4.2, p=0.0007), high versus intermediate (HR 2.56, 95%CI 1.6-4.2, p=0.0002), and high versus low (HR 6.36, 95%CI 3.7-10.8, p50% while selecting those most likely to benefit from dnDSA surveillance.

29 March 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
MLMurdoch Leeies
Murdoch Leeies
DCDavid Collister
David Collister
JHJulie Ho
Julie Ho
ATAaron Trachtenberg
Aaron Trachtenberg
JGJackie Gruber
Jackie Gruber
CHCarmen Hrymak
Carmen Hrymak
Sexual orientation and gender identity (SOGI)-diverse populations experience discrimination in organ and tissue donation and transplantation (OTDT) systems globally. We assembled a multidisciplinary group of clinical experts as well as SOGI-diverse patient and public partners and conducted a scoping review including citations on the experiences of SOGI-diverse persons in OTDT systems globally to identify and explore the inequities that exist with regards to living and deceased OTDT. Using scoping review methods, we conducted a systematic literature search of relevant electronic databases from 1970 to 2021 including a grey literature search. We identified and screened 2402 references and included 87 unique publications. Two researchers independently coded data in included publications in duplicate. We conducted a best-fit framework synthesis paired with an inductive thematic analysis to identify synthesized benefits, harms, inequities, justification of inequities, recommendations to mitigate inequities, laws and regulations, as well as knowledge and implementation gaps regarding SOGI-diverse identities in OTDT systems. We identified numerous harms and inequities for SOGI-diverse populations in OTDT systems. There were no published benefits of SOGI-diverse identities in OTDT systems. We summarized recommendations for the promotion of equity for SOGI-diverse populations and identified gaps that can serve as targets for action moving forward.

9 May 2024 in Clinical Transplantation
Verified
Journal Article
Open access
CRChristie Rampersad
Christie Rampersad
CWChris Wiebe
Chris Wiebe
RBRobert Balshaw
Robert Balshaw
JBJared Bullard
Jared Bullard
IGIan W. Gibson
Ian W. Gibson
JHJulie Ho
Julie Ho
Background: Immunosuppression reduction for BK polyoma virus (BKV) must be balanced against risk of adverse alloimmune outcomes. We sought to characterize risk of alloimmune events after BKV within context of HLA‐DR/DQ molecular mismatch (mMM) risk score.Methods: This single‐center study evaluated 460 kidney transplant patients on tacrolimus‐mycophenolate‐prednisone from 2010‐2021. BKV status was classified at 6‐months post‐transplant as “BKV” or “no BKV” in landmark analysis. Primary outcome was T‐cell mediated rejection (TCMR). Secondary outcomes included all‐cause graft failure (ACGF), death‐censored graft failure (DCGF), de novo donor specific antibody (dnDSA), and antibody‐mediated rejection (ABMR). Predictors of outcomes were assessed in Cox proportional hazards models including BKV status and alloimmune risk defined by recipient age and molecular mismatch (RAMM) groups.Results: At 6‐months post‐transplant, 72 patients had BKV and 388 had no BKV. TCMR occurred in 86 recipients, including 27.8% with BKV and 17% with no BKV (p = .05). TCMR risk was increased in recipients with BKV (HR 1.90, (95% CI 1.14, 3.17); p = .01) and high vs. low‐risk RAMM group risk (HR 2.26 (95% CI 1.02, 4.98); p = .02) in multivariable analyses; but not HLA serological MM in sensitivity analysis. Recipients with BKV experienced increased dnDSA in univariable analysis, and there was no association with ABMR, DCGF, or ACGF.Conclusions: Recipients with BKV had increased risk of TCMR independent of induction immunosuppression and conventional alloimmune risk measures. Recipients with high‐risk RAMM experienced increased TCMR risk. Future studies on optimizing immunosuppression for BKV should explore nuanced risk stratification and may consider novel measures of alloimmune risk.

28 March 2024 in Clinical Transplantation
Verified
Journal Article
Open access
CRChristie Rampersad
Christie Rampersad
WKWilliam Kong
William Kong
CWChris Wiebe
Chris Wiebe
RBRobert Balshaw
Robert Balshaw
JBJared Bullard
Jared Bullard
JHJulie Ho
Julie Ho
Background: There is variability in recommended viral monitoring protocols after kidney transplant. In response to increased demand for laboratory testing during the COVID‐19 pandemic, the Transplant Manitoba Adult Kidney Program updated its monitoring protocols for cytomegalovirus (CMV), Epstein‐Barr virus (EBV), and BK polyomavirus (BKV) to a reduced frequency.Methods: This single‐center nested case‐control study evaluated 252 adult kidney transplant recipients transplanted from 2015 to 2021, with the updated protocols effective on March 19th 2020. Cases included recipients transplanted after the protocol update who developed CMV, EBV, and BKV DNAemia and were matched to controls with DNAemia transplanted prior to the protocol update. The primary outcome was the difference in maximum DNA load titers between cases and matched controls. Secondary outcomes included time to initial DNAemia detection and DNAemia clearance. Safety outcomes of tissue‐invasive viral disease were described.Results: There were 216 recipients transplanted preupdate and 36 recipients postupdate. There was no difference between cases and controls in maximum or first DNA load titers for EBV, CMV, or BKV. Cases experienced earlier EBV DNAemia detection (26 (IQR 8, 32) vs. 434 (IQR 96, 1184) days, p = .005). Median follow‐up was significantly longer for recipients transplanted preupdate (4.3 vs. 1.3 years, p < .0001). After adjusting for follow‐up time, there was no difference in DNAemia clearance or tissue‐invasive viral disease.Conclusion: Our findings suggest that reduced frequency viral monitoring protocols may be safe and cost‐effective. This quality assurance initiative should be extended to detect longer‐term and tissue‐invasive disease outcomes.

16 July 2025 in Human Immunology
Verified
Journal Article
Closed access
EWEmmett Tsz Yeung Wong
Emmett Tsz Yeung Wong
RBRobert Balshaw
Robert Balshaw
IGIan W Gibson
Ian W Gibson
JHJulie Ho
Julie Ho
JSJamie Shaw
Jamie Shaw
CWChris Wiebe
Chris Wiebe